{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Theodoraki MN"],"funding":["Deutsche Forschungsgemeinschaft","NCI NIH HHS","National Institutes of Health","NIH"],"pagination":["1747732"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7153843"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["The molecular cargo of tumor-cell-derived exosomes (TEX) mimics that of parental tumor cells. Thus, TEX could potentially serve as noninvasive biomarkers of cancer progression. However, separation of TEX from non-TEX in patients' plasma requires tumor antigen-specific detection reagents. CD44v3 has been of interest as a potential biomarker of disease progression in HNSCC, because its overexpression in tumor cells associates with poor outcome. Here, CD44v3+ TEX immunocaptured from plasma of 44 HNSCC patients and 7 healthy donors (HDs) were evaluated as potential biomarkers of disease activity and stage. Exosomes were isolated from plasma of by size exclusion chromatography. Using anti-CD44v3 or anti-CD3 mAbs on beads, CD44v3+ TEX CD3(-)TEX-enriched exosomes were immunocaptured from supernat"],"journal":["Oncoimmunology"],"pubmed_title":["CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients' plasma as potential noninvasive biomarkers of disease activity."],"pmcid":["PMC7153843"],"funding_grant_id":["RO-1CA 168628","R01 CA168628","research fellowship # TH 2172/1-1","R21-C205644"],"pubmed_authors":["Theodoraki MN","Whiteside TL","Matsumoto A","Hoffmann TK","Beccard I"],"additional_accession":[]},"is_claimable":false,"name":"CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients' plasma as potential noninvasive biomarkers of disease activity.","description":"The molecular cargo of tumor-cell-derived exosomes (TEX) mimics that of parental tumor cells. Thus, TEX could potentially serve as noninvasive biomarkers of cancer progression. However, separation of TEX from non-TEX in patients' plasma requires tumor antigen-specific detection reagents. CD44v3 has been of interest as a potential biomarker of disease progression in HNSCC, because its overexpression in tumor cells associates with poor outcome. Here, CD44v3+ TEX immunocaptured from plasma of 44 HNSCC patients and 7 healthy donors (HDs) were evaluated as potential biomarkers of disease activity and stage. Exosomes were isolated from plasma of by size exclusion chromatography. Using anti-CD44v3 or anti-CD3 mAbs on beads, CD44v3+ TEX CD3(-)TEX-enriched exosomes were immunocaptured from supernat","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020","modification":"2025-04-22T08:39:49.507Z","creation":"2020-05-22T18:03:02Z"},"accession":"S-EPMC7153843","cross_references":{"pubmed":["32313730"],"doi":["10.1080/2162402X.2020.1747732"]}}